Related references
Note: Only part of the references are listed.In Vivo Cross-linking Reveals Principally Oligomeric Forms of α-Synuclein and β-Synuclein in Neurons and Non-neural Cells
Ulf Dettmer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
α-Synuclein mutations cluster around a putative protein loop
Eleanna Kara et al.
NEUROSCIENCE LETTERS (2013)
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease
Mickael Decressac et al.
BRAIN (2011)
Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity
Mohammed Emamussalehin Choudhury et al.
BRAIN RESEARCH (2011)
Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease
Hiroyasu Sato et al.
JOURNAL OF NEUROSCIENCE (2011)
Improved Immunodetection of Endogenous α-Synuclein
Byung Rho Lee et al.
PLOS ONE (2011)
Neuroprotective Effects of Zonisamide Target Astrocyte
Masato Asanuma et al.
ANNALS OF NEUROLOGY (2010)
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance
Patricia K. Sonsalla et al.
EXPERIMENTAL NEUROLOGY (2010)
Zonisamide: Aspects in neuroprotection
Thomas W. Roesler et al.
EXPERIMENTAL NEUROLOGY (2010)
Phosphorylated α-Synuclein at Ser-129 Is Targeted to the Proteasome Pathway in a Ubiquitin-independent Manner
Youhei Machiya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The Transgenic Overexpression of α-Synuclein and Not Its Related Pathology Associates with Complex I Inhibition
Virginie Loeb et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
How mitochondria produce reactive oxygen species
Michael P. Murphy
BIOCHEMICAL JOURNAL (2009)
Human α-Iduronidase Gene Transfer Mediated by Adeno-Associated Virus Types 1, 2, and 5 in the Brain of Nonhuman Primates: Vector Diffusion and Biodistribution
Carine Ciron et al.
HUMAN GENE THERAPY (2009)
A Novel Anti-Parkinsonian Agent, Zonisamide, Attenuates MPTP-Induced Neurotoxicity in Mice
Ryohei Yano et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2009)
Why Have We Failed to Achieve Neuroprotection in Parkinson's Disease?
C. Warren Olanow et al.
ANNALS OF NEUROLOGY (2008)
Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain
Latha Devi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Zonisamide improves motor function in Parkinson disease - A randomized, double-blind study
Miho Murata et al.
NEUROLOGY (2007)
Mechanisms of Parkinson's disease linked to pathological α-synuclein:: New targets for drug discovery
Virginia M. -Y. Lee et al.
NEURON (2006)
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy
CW Olanow et al.
MOVEMENT DISORDERS (2005)
Levodopa in the treatment of Parkinson's disease: Current controversies
CW Olanow et al.
MOVEMENT DISORDERS (2004)
Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells
S Yu et al.
NEUROSCIENCE LETTERS (2004)
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
A Schober
CELL AND TISSUE RESEARCH (2004)
Caught in the act:: α-synuclein is the culprit in Parkinson's disease
JL Eriksen et al.
NEURON (2003)
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
S Zolotukhin et al.
METHODS (2002)
Dopamine-dependent neurotoxicity of α-synuclein:: A mechanism for selective neurodegeneration in Parkinson disease
J Xu et al.
NATURE MEDICINE (2002)
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
D Blum et al.
PROGRESS IN NEUROBIOLOGY (2001)
Vesicle permeabilization by protofibrillar α-synuclein:: Implications for the pathogenesis and treatment of Parkinson's disease
MJ Volles et al.
BIOCHEMISTRY (2001)
An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
CW Olanow et al.
NEUROLOGY (2001)
Share Paper
